Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(R)-Thalidomide is the R-enantiomer of Thalidomide, has sedative properties. 在相同实验条件下,摩尔浓度相同的化合物盐形式与游离态具有相同的生物活性,但盐形式 Thalidomide 5-fluoride 的水溶性和稳定性通常比游离态更好。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
100 mg | 待询 | 5日内发货 | ||
500 mg | 待询 | 5日内发货 |
(R)-Thalidomide 的其他形式现货产品:
产品描述 | (R)-Thalidomide is the R-enantiomer of Thalidomide, has sedative properties. |
体外活性 | With the affinity of (R)-Thalidomide by the MIP present surface capture, that is more strongly than the other forms. In the case of (R)-Thalidomide, it is found to bind to the selective sites of the MIP more strongly than the other which reflects their different biological entities[1]. The (S)-Thalidomide imprints MIP nanoparticles exerted a greater cytotoxic effect on the caco-2 cells than the (R)-Thalidomide imprinted MIPs[1]. |
体内活性 | Effectiveness of oral thalidomide alone, and with intraperitoneal BCNU or cisplatin combination chemotherapy, is assessed after several weeks treatment. Both serum and tissue concentrations of (R)-thalidomide are 40-50% greater than those of (S)-thalidomide. Co-administration of BCNU or cisplatin with thalidomide did not alter the concentration enantioselectivity[1]. |
别名 | (R)-(+)-Thalidomide |
分子量 | 258.23 |
分子式 | C13H10N2O4 |
CAS No. | 2614-06-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(R)-Thalidomide 2614-06-4 Others (R) Thalidomide Thalidomide (R)Thalidomide (R)-(+)-Thalidomide Inhibitor inhibitor inhibit